COVID-19 Phase III Trial Design: Big Ambitions, Little Consistency
Executive Summary
As remdesivir’s change in primary endpoint illustrates, there are many ways to measure potential treatments. A Pink Sheet analysis of 50 Phase III clinical trial protocols found numerous different approaches. Adaptive trials seems critical for speed, but a survival endpoint seems essential for durability.
You may also be interested in...
For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
US FDA Pushing Coronavirus Trial Sponsors To Include Control Groups
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”
US FDA Welcomes Variety Of Phase II/III Trial Designs For COVID-19 Therapies, But With Standards
Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.